Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a report published on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The firm has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a twelve month low of $0.01 and a twelve month high of $1.99.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More

• Five stocks we like better than Athersys
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Microsoft Can Hit New All-Time Highs This Year – Here’s Why
• What is the Australian Securities Exchange (ASX)
• Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
• How to buy stock: A step-by-step guide for beginners 
• IonQ’s Quantum Surge: Ride the Wave or Cash Out?